Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2013

01-11-2013 | Original Article

Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes

Authors: Cielito C. Reyes-Gibby, Michael D. Swartz, Xiaoying Yu, Xifeng Wu, Sriram Yennurajalingam, Karen O. Anderson, Margaret R. Spitz, Sanjay Shete

Published in: Supportive Care in Cancer | Issue 11/2013

Login to get access

Abstract

Purpose

Symptom clusters, the multiple, co-occurring symptoms experienced by cancer patients, are debilitating and affects quality of life. We assessed if a panel of immune-response genes may underlie the co-occurrence of severe pain, depressed mood, and fatigue and help identify patients with severe versus non-severe symptom clusters.

Methods

Symptoms were assessed at presentation, prior to cancer treatment in 599 newly diagnosed lung cancer patients. We applied cluster analyses to determine the patients with severe versus non-severe symptom clusters of pain, depressed mood, and fatigue.

Results

Two homogenous clusters were identified. One hundred sixteen patients (19 %) comprised the severe symptom cluster, reporting high intensity of pain, depressed mood, and fatigue and 183 (30 %) patients reported low intensity of these symptoms. Using Bayesian model averaging methodology, we found that of the 55 single nucleotide polymorphisms assessed, an additive effect of mutant alleles in endothelial nitric oxide synthase (-1474 T/A) (posterior probability of inclusion (PPI) = 0.78, odds ratio (OR) = 0.54, 95 % credible interval (CI) = (0.31, 0.93)); IL1B T-31C (PPI = 0.72, OR = 0.55, 95 % CI = (0.31, 0.97)); TNFR2 Met196Arg (PPI = 0.70, OR = 1.85, 95 % CI = (1.03, 3.36)); PTGS2 exon 10+837T > C (PPI = 0.69, OR = 0.54, 95 % CI = (0.28, 0.99)); and IL10RB Lys47Glu (PPI = 0.68; OR = 1.74; 95 % CI = (1.04, 2.92)) were predictive for symptom clusters.

Conclusions

Genetic polymorphisms may facilitate identification of high-risk patients and development of individualized symptom therapies.
Literature
1.
Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S (2008) Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9(8):777–785PubMedCrossRef
2.
Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Reid LD, Turrisi AT III, Unutzer J et al (2004) National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst Monogr 32:9–16PubMed
3.
4.
Maier SF, Watkins LR (2003) Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun 17(Suppl 1):S125–S131PubMedCrossRef
5.
Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21(4):413–427PubMedCrossRef
6.
Watkins LR, Maier SF (1999) Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci U S A 96(14):7710–7713PubMedCrossRef
7.
Anisman H, Ravindran AV, Griffiths J, Merali Z (1999) Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 4(2):182–188PubMedCrossRef
8.
Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158(8):1252–1257PubMedCrossRef
9.
Rakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P (2008) Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 4:64PubMedCrossRef
10.
Rausch SM, Gonzalez BD, Clark MM, Patten C, Felten S, Liu H, Li Y, Sloan J, Yang P (2012) SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer 77(1):217–223PubMedCrossRef
11.
Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P (2007) Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1–2):25–30PubMedCrossRef
12.
Reyes-Gibby CC, Spitz M, Wu X, Merriman K, Etzel C, Bruera E, Kurzrock R, Shete S (2007) Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev 16(12):2745–2751PubMedCrossRef
13.
Reyes-Gibby CC, El OB, Spitz MR, Parsons H, Kurzrock R, Wu X, Shete S, Bruera E (2008) The influence of tumor necrosis factor-alpha -308 G/A and IL-6–174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev 17(11):3262–3267PubMedCrossRef
14.
Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR (2009) Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage 38(6):894–902PubMedCrossRef
15.
Reyes-Gibby CC, Spitz MR, Yennurajalingam S, Swartz M, Gu J, Wu X, Bruera E, Shete S (2009) Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev 18(10):2636–2642PubMedCrossRef
16.
Swartz MD, Kimmel M, Mueller P, Amos CI (2006) Stochastic search gene suggestion: a Bayesian hierarchical model for gene mapping. Biometrics 62(2):495–503PubMedCrossRef
17.
Swartz MD, Yu RK, Shete S (2008) Finding factors influencing risk: comparing Bayesian stochastic search and standard variable selection methods applied to logistic regression models of cases and controls. Stat Med 27(29):6158–6174PubMedCrossRef
18.
Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92(21):1764–1772PubMedCrossRef
19.
Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F (2002) Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23(3):239–255PubMedCrossRef
20.
Vilaseca I, Chen AY, Backscheider AG (2006) Long-term quality of life after total laryngectomy. Head Neck 28(4):313–320PubMedCrossRef
21.
Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233PubMedCrossRef
22.
Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR (2007) Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67(13):6520–6527PubMedCrossRef
23.
24.
Barbieri MM, Berger JO (2004) Optimal predictive model selection. Ann Stat 32(3):870–897, 2010CrossRef
25.
Viallefont V, Raftery AE, Richardson S (2001) Variable selection and Bayesian model averaging in case-control studies. Stat Med 20(21):3215–3230PubMedCrossRef
26.
Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ, Rafie-Kolpin M, Hsieh CM et al (2006) Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 15(4):519–529PubMedCrossRef
27.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404(6776):398–402PubMedCrossRef
28.
Martucci C, Trovato AE, Costa B, Borsani E, Franchi S, Magnaghi V, Panerai AE, Rodella LF, Valsecchi AE, Sacerdote P, Colleoni M (2008) The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain 137(1):81–95PubMedCrossRef
29.
Neeb L, Hellen P, Boehnke C, Hoffmann J, Schuh-Hofer S, Dirnagl U, Reuter U (2011) IL-1beta stimulates COX-2 dependent PGE synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One 6(3):e17360PubMedCrossRef
30.
Baune BT, Dannlowski U, Domschke K, Janssen DG, Jordan MA, Ohrmann P, Bauer J, Biros E, Arolt V, Kugel H, Baxter AG, Suslow T (2010) The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 67(6):543–549PubMedCrossRef
31.
Von Ah DM, Kang DH, Carpenter JS (2008) Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs 31(2):134–144CrossRef
32.
Ferreira SH, Lorenzetti BB, Bristow AF, Poole S (1988) Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334(6184):698–700PubMedCrossRef
33.
Maier SF, Wiertelak EP, Martin D, Watkins LR (1993) Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 623(2):321–324PubMedCrossRef
34.
Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E (1993) Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 150(8):1189–1193PubMed
35.
Reinertsen KV, Grenaker Alnaes GI, Landmark-Hoyvik H, Loge JH, Wist E, Kristensen VN, Fossa SD, Edvardsen H (2011) Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun 25(7):1376–1383. doi:10.​1016/​j.​bbi.​2011.​04.​001 PubMedCrossRef
36.
Gelinas C, Fillion L (2004) Factors related to persistent fatigue following completion of breast cancer treatment. Oncol Nurs Forum 31(2):269–278PubMedCrossRef
37.
Muller N, Riedel M, Schwarz MJ (2004) Psychotropic effects of COX-2 inhibitors—a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37(6):266–269PubMedCrossRef
38.
Dolan S, Field LC, Nolan AM (2000) The role of nitric oxide and prostaglandin signaling pathways in spinal nociceptive processing in chronic inflammation. Pain 86(3):311–320PubMedCrossRef
39.
Nijs J, Van de Velde B, De Meirleir K (2005) Pain in patients with chronic fatigue syndrome: does nitric oxide trigger central sensitisation? Med Hypotheses 64(3):558–562PubMedCrossRef
40.
Thabet S, Ben NM, Zaafrane F, Gaha L, Ben SK, Romdhane A, Nour M, Jrad BB (2011) Association of the Met-196-Arg variation of human tumor necrosis factor receptor 2 (TNFR2) with paranoid schizophrenia. J Mol Neurosci 43(3):358–363PubMedCrossRef
41.
Jensen MP (2003) The validity and reliability of pain measures in adults with cancer. J Pain 4(1):2–21PubMedCrossRef
42.
Butt Z, Wagner LI, Beaumont JL, Paice JA, Peterman AH, Shevrin D, Von Roenn JH, Carro G, Straus JL, Muir JC, Cella D (2008) Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 35(1):20–30PubMedCrossRef
Metadata
Title
Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes
Authors
Cielito C. Reyes-Gibby
Michael D. Swartz
Xiaoying Yu
Xifeng Wu
Sriram Yennurajalingam
Karen O. Anderson
Margaret R. Spitz
Sanjay Shete
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1885-5

Other articles of this Issue 11/2013

Supportive Care in Cancer 11/2013 Go to the issue

Review Article

Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients

Erratum

Erratum to: Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor

Special Article

Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results

Original Article

Lower limb lymphedema in gynecological cancer survivors—effect on daily life functioning

Editorial

The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact

Letter to the editor

Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits